Goldline Pharmaceutical IPO Details
The Goldline Pharmaceutical IPO is a book build issue with a total issue size of ₹12 cr, comprising of fresh issue of 2562000 equity shares. Goldline Pharmaceutical IPO opened for subscription on May 12, 2026 and closed on May 14, 2026. Goldline Pharmaceutical IPO is set price band at ₹41 to ₹43 per share, with a lot size of 3000 shares. Minimum investment for Retail investors was ₹258,000.00 (at the upper price band) to apply for one lot.
The basis of allotment got finalized on May 15, 2026, and listed on both the NSE and BSE on May 19, 2026.
Bigshare Services Pvt Ltd has been appointed as the registrar. Cumulative Capital Private Limited are the Book Running Lead Manager for the issue.
Before investing in the Goldline Pharmaceutical IPO, investors should review the company's financial performance, business objectives, and risk factors mentioned in the offer documents and apply before the subscription window closes.
- Price Band
- ₹ 41 – 43
- Lot Size
- 3000
- Issue Size
- ₹12 Cr
- Minimum Investment
- ₹258000 (6000 Shares)
- Listing Date
- 19 May 2026
Current GMP
₹15 (+34.88%)
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
About Goldline Pharmaceutical Limited
Goldline Pharma comprises 42 products catering to a wide range of medical specialties, including Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology. This division focuses on delivering quality formulations for acute and chronic healthcare requ
Go
Goldline Cardinal includes 54 products developed for the specialty healthcare segment. The division primarily serves Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians, offering therapies focused on lifestyle
Goldline Aayushman
Goldline Aayushman consists of 18 products designed for Pediatricians, Child Specialists, Neonatologists, and General Practitioners. The division focuses on pediatric and neonatal healthcare solutions aimed at supporting child wellness and development.
Goldline InLife
Goldline InLife offers 22 products catering to Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians. The division is focused on critical care and specialty treatments required in advanced healthcare settings and hospitals.
Goldline Wellness
Goldline Wellness comprises 10 products dedicated to supportive care in cancer therapy and patient wellness management. The division emphasizes improving patient care and quality of life during treatment.
The company follows an asset-light business model and does not manufacture pharmaceutical products directly. Instead, it collaborates with third-party manufacturers who produce medicines based on the company’s market research, product specifications, and quality standards, while ensuring compliance with applicable pharmaceutical regulations.
All products are marketed and sold under the “Goldline” brand through a well-established distribution network comprising distributors, retailers, and wholesalers. The company currently partners with 15 manufacturers and 7 distributors to ensure efficient supply chain management and market reach.
In addition to pharmaceutical marketing and distribution, the company also supports hospitals and healthcare institutions through procurement assistance and material supply services.
Goldline Pharmaceuticals has established its presence across multiple Indian states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Goldline Pharmaceutical IPO Promoters
- Amol Laxmikant Mujumdar
- Swapan Premprakash Khandelwal
Promoters Holding
Holding Pre Issue
79.70%
Holding Post Issue
0.00%
Goldline Pharmaceutical IPO Objective
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company
- General corporate purposes
Address / Contact Info
Goldline Pharmaceutical Ltd. Address
103, F-1, Leela Apartment, Shilpa HSG Society,
Near Saptagiri Nagar, Shanidham,
Narendra Nagar,
Nagpur, Maharashtra, 440015
Email: info@goldlinepharma.in
Tel: +91 712 278 6666
Website:http://www.goldlinepharma.in/
IPO Snapshot
Book Running Lead Managers
- Cumulative Capital Private Limited
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Goldline Pharmaceutical IPO is a Book-building IPO with a total issue size of ₹12 crore. The Goldline Pharmaceutical IPO price band is ₹41 to 43 per share. The Goldline Pharmaceutical IPO subscription opens on Tue, May 12, 2026, and closes on Thu, May 14, 2026. The Goldline Pharmaceutical IPO will be listed on the BSE. Bigshare Services Pvt Ltd is the registrar for the Goldline Pharmaceutical IPO.
The Goldline Pharmaceutical IPO opens on Tue, May 12, 2026 and closes on Thu, May 14, 2026
Goldline Pharmaceutical IPO Price Band is ₹41 to 43 per share.
Goldline Pharmaceutical IPO lot size is 3000 shares, Retail investors need a minimum investment of ₹258000 based on the upper price band
The minimum investment for Goldline Pharmaceutical IPO is ₹258000, based on one lot of 3000 shares at the upper price band of ₹43 per share.
Investors can apply for the Goldline Pharmaceutical IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Thu, May 14, 2026. The application amount remains blocked until the Goldline Pharmaceutical IPO allotment is finalized.
Goldline Pharmaceutical IPO issue size is ₹12 crores.
Goldline Pharmaceutical IPO allotment date is Wed, Jul 1, 2026.
The registrar for Goldline Pharmaceutical IPO is Bigshare Services Pvt Ltd. Investors can go to Bigshare Services Pvt Ltd website to check Goldline Pharmaceutical IPO allotment status, refund processing, and other IPO-related information.
The Goldline Pharmaceutical IPO GMP (Grey Market Premium) is ₹15 as of Tue, May 19, 2026. Based on the upper price band of ₹43 per share, the estimated Goldline Pharmaceutical IPO listing price is ₹58, indicating a potential listing gain of approximately 0% over the issue price.